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Abbreviations: 
ICHD3-beta: International Classification of Headache Disorders 3-beta 
SUNCT: Short lasting unilateral neuralgiform headache attacks with conjunctival injection and 
tearing 
SUNA: Short lasting unilateral neuralgiform headache attacks with autonomic features 
ONS: Occipital nerve stimulation 
VTA: Ventral tegmental area 
DBS: Deep brain stimulation 
NHS: National Health Service 
HAL: Headache load 
VRS: Verbal rating scale 
MIDAS: Migraine Disability Assessment Scores 
HIT-6: Headache Impact Test Scores 
BDI-II: Beck Depression Inventory II Score 
HAD-A: Hospital Anxiety and Depression Score, Anxiety component 
HAD-D: Hospital Anxiety and Depression Score, Depression component 
EQ-5D: EuroQoL Score 
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SF36: Short-Form 36 Score (SF36P – physical component, SF36M – mental component) 
IPG: Implantable pulse generator 
IQR: Interquartile range 
CCH: chronic cluster headache 
 
 
 
 
 
 
 
 
 
 
 
 
ABSTRACT 
Running Title: DBS SUNCT/SUNA 
Pg. 4 
 
Short-lasting unilateral neuralgiform headache attacks are primary headache conditions 
characterized by short lasting attacks of unilateral pain accompanied by autonomic features.  A 
small minority are refractory to medical treatment.  Neuroimaging studies have suggested a 
role of the posterior hypothalamic region in their pathogenesis.  Previous case reports on deep 
brain stimulation of this region, now understood to be the ventral tegmental area, for this 
condition are limited to a total of three patients.  We present outcomes on a cohort of 11 new 
patients treated with ventral tegmental area deep brain stimulation in an uncontrolled open-
label prospective study. 
Eleven patients with refractory short-lasting unilateral neuralgiform headache attacks 
underwent ipsilateral ventral tegmental area deep brain stimulation in a specialist unit.  All 
patients had failed, or been denied access to, occipital nerve stimulation within the United 
Kingdom’s National Health Service.  Primary endpoint was change in mean daily attack 
frequency at final follow-up.  Secondary outcomes included attack severity, attack duration, 
headache load, quality of life measures, disability and affective scores.  Information was also 
collected on adverse events. 
Eleven patients (seven male) with a median age of 50 years (range 26-67) were implanted 
between 2009 and 2014.  Median follow-up was 29 months (range 7-63).  At final follow-up 
the median improvement in daily attack frequency was 78% (IQR 33%).  Response rate 
(defined as at least a 50% improvement in daily attack frequency) was 82% and four patients 
were rendered pain free for prolonged periods of time.  Headache load (a composite score of 
attack frequency, severity and duration) improved by 99% (IQR 52%).  Improvements were 
observed in a number of quality of life, disability and affect measures.  Adverse events included 
mild incision site pain, subcutaneous displacement of the implantable pulse generator, transient 
oscillopsia and minor wound infection.  One patient required removal of the system due to 
wound infection. 
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Ventral tegmental area deep brain stimulation may be an effective treatment option for 
refractory short-lasting unilateral neuralgiform headache attack patients who have failed other 
therapies. 
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INTRODUCTION 
Short-lasting unilateral neuralgiform headache attacks are a rare form of primary headache 
characterised by frequent attacks of excruciating unilateral pain occurring in the trigeminal 
distribution, centred on the eye and temple, with associated autonomic features.  They are 
included in the group known as the trigeminal autonomic cephalalgias and The International 
Classification of Headache Disorders (ICHD3-beta) describes two subtypes (Table 1): short-
lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing 
(SUNCT) and short-lasting unilateral neuralgiform headache attacks with cranial autonomic 
features (SUNA) (Headache Classification Committee of the International Headache, 2013).  
The condition is said to be chronic when it occurs for more than a year with remission periods 
lasting less than one-month.  Short-lasting unilateral neuralgiform headache attacks can be 
difficult to treat medically.  In the past, intractable patients have been subjected to destructive 
procedures of the trigeminal nerve with poor long-term results (Black and Dodick, 2002).  
Peripheral (occipital nerve stimulation [ONS]) and central (ventral tegmental area [VTA] deep 
brain stimulation [DBS]) neuromodulation techniques have been carried out with more 
promising results (Leone et al., 2005, Lyons et al., 2009, Bartsch et al., 2011, Lambru et al., 
2014).   
To date there are three published case reports of DBS for short-lasting unilateral neuralgiform 
headache attacks (Leone et al., 2005, Lyons et al., 2009, Bartsch et al., 2011).  We present a 
consecutive series of 11 patients with intractable chronic short-lasting unilateral neuralgiform 
headache attacks treated with VTA-DBS as a humanitarian intervention reporting on changes 
in attack characteristics, quality of life, headache disability, affect scores and adverse events. 
PATIENTS AND METHODS 
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This was an observational study based on a prospective, open label cohort initiated in 2009. 
Under the supervision of our institution’s Clinical Effectiveness Supervisory Committee with 
arrangements for clinical governance, consent and audit, we offered VTA-DBS to medically 
intractable short-lasting unilateral neuralgiform headache attacks who had failed ONS or had 
been declined NHS funding for ONS. The procedure was provided on the basis of a 
“humanitarian intervention”. In addition, ethic board approval for data collection and 
publication was granted by Northwick Park Hospital Research Ethics Committee, Hampstead, 
London, UK.   
All patients were seen by a single specialist headache team at the National Hospital for 
Neurology and Neurosurgery, Queen Square, London UK and referred to a single 
multidisciplinary DBS team at the same centre.  All patients fulfilled the International 
Classification of Headache Disorders-2 criteria at diagnosis but also met revised ICHD-3beta 
criteria (Headache Classification Subcommittee of the International Headache Society., 2004, 
Headache Classification Committee of the International Headache, 2013).  Patients with 
prolonged attacks had a trial of Indometacin (oral or intramuscular) to rule out Indometacin-
sensitive headaches (Antonaci et al., 2003).  Unlike chronic cluster headache or chronic 
migraine, intractability is not defined for short-lasting unilateral neuralgiform headache attacks 
(Goadsby et al., 2006).  Patients were considered suitable for VTA-DBS if they had had 
disabling, medically intractable chronic short-lasting unilateral neuralgiform headache attacks 
for at least two years and had failed adequate trials of lamotrigine, topiramate, gabapentin, 
pregabalin and at least one of either carbamazepine or oxcarbazepine (Lambru et al., 2014).  
Agents were selected on the basis of reported efficacy in this condition and local experience 
(Cohen et al., 2006, Williams and Broadley, 2008).  A failed trial was defined as lack of 
response, intolerable side effects or contradiction to the use of the drug.  One patient (P9) did 
not meet the criteria for medical intractability as they had not trialled carbamazepine or 
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oxcarbazepine but this patient was implanted primarily for co-existent intractable chronic 
cluster headache.  All patients were considered for ONS prior to VTA-DBS and had either been 
declined funding or failed to respond.  Microvascular decompression of the trigeminal nerve 
was not being offered to this patient group during the study period.  Neuropsychological 
evaluations and MRI brain scans were performed to exclude possible contraindications to 
surgery such as significant cognitive impairment, brain lesion or significant brain atrophy. 
Outcomes 
The two primary outcome measures were the change in median daily attack frequency from 
baseline to final follow-up and clinical response to VTA-DBS defined as an at least 50% 
reduction in daily attack frequency.  Secondary outcomes included reduction in the daily attack 
severity and frequency, headache specific disability scores, quality of life and affect scores.  
Outcome data was collected and recorded prospectively.  Patients were seen at three monthly 
intervals post implant over the first year and six monthly thereafter.  Timing of additional 
appointments was dependent on clinical condition.  Data collected included demographics, 
diagnosis, previous and current treatments, attack frequency, attack severity, headache load, 
headache disability scores, quality of life scales, affective scores, DBS settings and 
complications.   
Headache load (HAL) is a composite score defined as Σ(severity [verbal rating scale]) x 
(duration [hours]) of all attacks over a two week period (Levy et al., 2004).   Patients were 
asked to record these data in a headache diary completed for at least two weeks before every 
assessment.  Headache severity was measured on a verbal rating scale (VRS; 0=no pain – 
10=excruciating pain).  Patients with multiple headache types were able to differentiate their 
phenotypes and kept a separate diary for each headache syndrome.    
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Although specific tools for measuring the associated disability of trigeminal autonomic 
cephalalgias have yet to be validated, Migraine Disability Assessment Scores (MIDAS) and 
Headache Impact Test-6 Scores (HIT-6) were recorded pre and post-DBS to monitor disability.  
These scores have been widely used in the assessment of primary headache disorders and have 
previously been used to monitor response to cluster headache, hemicrania continua and short-
lasting unilateral neuralgiform disorders in ONS (Schwedt et al., 2007, Burns et al., 2009, 
Lambru et al., 2014).  Beck Depression Inventory II Score (BDI-II), Hospital Anxiety (HAD-
A) and Depression (HAD-D) Scores were used to monitor mental state pre- and post-ONS 
implant and quality of life was assessed using the EuroQoL (EQ-5D) and Short-Form 36 
(SF36).  
Data were collected prospectively and entered onto a clinical database (Microsoft Excel, 
Microsoft Corporation, Redmond, WA, USA).  
Surgical Procedure 
Deep brain stimulation surgery was performed with the Leksell frame (model G, Elekta 
Instrument AB, Stockholm, Sweden), using an MRI-guided and MRI-verified approach 
without microelectrode recording.  This approach has previously been described for alternative 
DBS targets (Holl et al., 2010, Foltynie et al., 2011).  Surgery was performed under local 
anaesthesia for patients one to four and under general anaesthesia for all others (P5-11).  The 
anatomical target was the VTA ipsilateral to the side of attacks.  The location of the deepest 
contact of the Medtronic 3389 lead was defined on an axial 1.5T T2-weighted stereotactic MRI 
image at a level immediately above the mammillary bodies, anteromedial to the hypointense 
red nucleus and posterolateral to the hypointense mammillothalamic tract. Postoperatively, 
electrode position was verified using a stereotactic MRI (or CT in patient 8 with ONS in situ) 
(Fig 1).  MRI in patients with implanted ONS or DBS hardware was obtained using a low 
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energy protocol (Zrinzo et al., 2011). All DBS leads were implanted within 1mm of the 
intended target point.  The lead was then connected to a Medtronic implantable pulse generator 
(IPG) located in the infra-clavicular region. 
DBS Programming 
Prior to hospital discharge all patients underwent initial programming to define optimal 
stimulation parameters.  The contact point that produced typical patient complaints of transient 
vertical diplopia, vertigo, oscillopsia and ophthalmoplegia at the lowest amplitudes was chosen 
as the initial stimulation contact.  Four patients had stimulation started immediately and all 
remaining patients had a delay of four to seven weeks before stimulation was started.  This 
delay was due to patients exhibiting a stun effect post-operatively where attacks transiently 
improved without use of stimulation.  In those with a stun effect, DBS was not initiated until 
attacks returned to normal pre-surgical frequency.  All devices were programmed with 
frequency of 185Hz and a 60μs pulse width.  Voltage was adjusted according to patient reported 
side effects (see above) aiming for a maximum of 4.0V.  Adjustments in voltage were 
undertaken in single or multiple steps dependent on patient tolerability.  Stimulation parameters 
remained constant for three months after each re-programming session.  Adjustments in 
stimulation parameters were made depending on clinical response.  
Statistics 
All statistical analyses were conducted using IBM SPSS Statistics version 22 (IBM Corp. Int.).  
In descriptive analysis, continuous variables were summarized using median and interquartile 
range and categorical variable using percentages.  Wilcoxon signed-rank tests were used to 
measure changes in baseline values.  A last observation carried forward technique was used in 
the case of missing data. All statistical tests were two-sided with a significance level of 5%.   
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RESULTS 
Patient demographics 
Eleven patients (six male) with short-lasting unilateral neuralgiform headache attacks 
underwent VTA-DBS between October 2009 and September 2014.  Patient demographics and 
baseline headache characteristics are shown in Table 2.  Median age at implant was 50 years 
(range 26-67).  Three patients were diagnosed with SUNA and eight SUNCT.  Nine patients 
had been chronic since onset.  Median duration of the chronic phase was 9 years (range 4-20).  
Five patients had additional headache syndromes including chronic migraine (three patients), 
chronic cluster headache (three patients) (Table 2).  In those with cluster headache, attacks of 
short-lasting unilateral neuralgiform headache attacks were ipsilateral to their cluster attacks 
in all but one patient (P9) who had left sided cluster attacks and unilateral but side variable 
SUNCT attacks (more common on the left).  Eight patients had unilateral DBS electrodes 
implanted and three had bilateral implants (P9 and P10) for side variable attacks 
(Supplementary Table 4).  Two patients (P5 and P9) had previously undergone ONS 
implantation with little (P9) or no effect (P5) on their SUNCT.  Patient 5 had had the ONS 
device removed prior to VTA-DBS and Patient 10 still had the ONS in-situ given its partial 
effect on their cluster headaches. 
All patients had undergone MRI brain scans prior to VTA-DBS of which two showed evidence 
of neurovascular conflict of the ipsilateral trigeminal nerve.  
Patients had tried a median of 11 treatments (IQR 3) including oral preventative drugs and 
injectable treatments (Supplementary Table 1 and 2).  Nine of ten patients that received 
lidocaine infusions reported transient benefit and ten patients failed to receive any benefit from 
greater occipital nerve blocks.  
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Follow up and Final outcome  
Post-operative follow-up ranged from seven to 63 months with a median of 29 months (IQR 
20).  One patient had her DBS system removed at time of follow-up.   
At final follow up, median attack frequency had reduced by 78% (IQR 33) from 45 (IQR 10) 
to 2 (IQR 180) attacks per day (p=0.003) (Fig 2 and Table 3).  A positive clinical response, 
defined as at least a 50% reduction in attack frequency, was seen in 82% (9 patients).   
Of the two who failed to respond, one (P5) had the stimulator switched off for around 12 
months during the 32-month follow-up due to tolerability issues but still obtained a more than 
30% reduction in attacks.  The other (P6), reporting a 25% reduction in attack frequency at 
follow-up did not have an implant in-situ having had the DBS system removed 17 months into 
her 24 month follow-up due to a wound infection.  Previous to implant removal, the patient 
was reporting a 90% reduction in daily attack frequency. 
Patient estimate of improvement was 70% (IQR 95%) (Table 3) and all patients said they would 
recommend the treatment to others.  The median time to reach a 50% improvement was 1 
month (range 1-2 months).  Only one responder had the system switched off for any period of 
time (P6) and attack frequency returned to baseline within 1 month of DBS removal. 
In those with co-existent headache conditions, cluster headache attacks decreased in two 
patients (P3 and P9) by 72% and 25% respectively.  Migrainous headaches failed to respond 
in the three patients (P3, P6 and P10) reporting them. 
Attack severity, duration and headache load  
At final follow-up, median attack severity reduced by 50% from 10 (IQR 2) to 5 (IQR 10) 
points on VRS (p=0.020).  Median attack duration reduced by 99% (IQR 100) from 7200 to 30 
seconds but this change was not statistically significant (p=0.066).  Headache load showed a 
Running Title: DBS SUNCT/SUNA 
Pg. 13 
 
median reduction of 99% (IQR 52) (p=0.026).  Neither of the patients categorized as clinical 
non-responders (P5 and P6) showed a more than 50% reduction in HAL.  One patient (P9) who 
recorded a 66% reduction in attack frequency failed to show a matching response to HAL (48% 
reduction) (Table 3).  
Headache associated disability scores, quality of life and affect measures  
Baseline median MIDAS and HIT-6 scores were 81 (IQR 254) and 70 (IQR 12) respectively, 
both scores being within the severely affected range (Table 4).  At final follow-up statistically 
significant reductions were seen in HIT-6 but not MIDAS.  Median HIT-6 fell by 15 points 
(p=0.015) well above the three point minimally important change (Smelt et al., 2014).  MIDAS 
fell by 39 points (p=0.678) which although not statistically significant is above the nine-point 
difference separating moderate from severe disability. 
Summary measures of the physical (SF-36P) and mental (SF-36M) SF-36 scale showed a non-
significant improvement (Table 3).  No significant change was seen in the separate domain 
scores of SF-36 scale (Figure 3).  Euro-QoL 5D and EuroScale scores did not show any 
significant change post implant (Table 4).  Prior to implant all affective scores indicated the 
presence of moderate mood disorders.  Post treatment, both HAD-A and BDI-II scales 
indicated mild disorder scores but HAD-D continued to indicate moderate levels of depression 
(Table 4).  Despite this clinical change, there was no statistically significant change in affective 
scores at follow-up.     
Adverse Events 
Adverse events were recorded if any issues had arisen during the time of treatment.  Events 
were classified as “hardware related” if they involved a malfunction of any device component, 
“biological” if they involved pain or other biological reactions related to the device or the 
surgical procedure to implant it and “stimulation-related” if they were thought to be related to 
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stimulation. One hardware related event was noted with a patient requiring surgical revision of 
their IPG due to the IPG moving or “flipping”.  Biological adverse events included mild to 
moderate neck stiffness in three patients, keloid scar in one patient and persistent pain over 
wound sites in two patients. One patient suffered a small wound dehiscence in the first three 
weeks post-operatively with no evidence of wound infection. One patient suffered a wound 
infection at the lead/cable connector site 17 months post-implant (P6).  Due to the risk of spread 
of infection, the whole DBS system was removed.  All patients reported transient stimulation 
related adverse effects (described in DBS programming section above) related to DBS 
programming resolving within minutes to hours.  One patient complained of symptoms 
compatible with oscillopsia on reading for six weeks after their initial programming session 
that resolved spontaneously.  One patient (P5) complained of intolerable worsening of chronic 
nausea with any change in stimulation, however, with blinded changes in stimulation and in a 
12-month period without stimulation there was no change in the nausea and it was judged that 
this complaint was not related to stimulation.  A total of two surgical interventions were 
required during follow-up (Table 5). 
Concomitant drug use 
Nine patients were taking preventative medications for short lasting unilateral neuralgiform 
headache attacks at time of implant (Supplementary Table 3).  At final follow-up, four patients 
had stopped all preventatives for their SUNCT/SUNA and a further two had been able to reduce 
their doses of one or more medications.   
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Stimulation parameters 
A summary of stimulation parameters is given in Supplementary Table 4.  Median stimulation 
amplitude at follow-up was 3.0V.  Subjects had a median of 6 changes to stimulation 
parameters during follow-up.   
 
DISCUSSION 
Previous case reports of VTA-DBS treatment in short lasting unilateral neuralgiform headache 
attacks have suggested a benefit in three patients (Leone et al., 2005, Lyons et al., 2009, 
Bartsch et al., 2011).  Our open-label prospective series of eleven patients suggests that VTA-
DBS may be an effective and safe treatment in patients with intractable short lasting unilateral 
neuralgiform headache attacks who have proved refractory to all other available treatment 
modalities.  In our group of eleven patients there was a significant reduction in daily attack 
frequency of 78% with four patients remaining pain free for prolonged periods of time.  Overall 
nine patients had a positive response to VTA-DBS with a 50% or more reduction in attack 
frequency.  Improvement was seen in headache specific disability scores (HIT-6) but not in 
quality of life scales or measures of depression. 
Deep brain stimulation for another trigeminal autonomic cephalalgia chronic cluster headache 
(CCH) was first undertaken by Leone et al in 2001 (Leone et al., 2001).  This procedure was 
based on the findings of a 1998 study which showed increased activation on positron emission 
tomography in the posterior hypothalamic region during cluster headache attacks (May et al., 
1998).  To date, there is now published data on over 70 patients with intractable CCH treated 
with DBS.  One series which pools 58 of these patients reports that 62% showed a 50% or 
greater reduction in attack frequency (Magis and Schoenen, 2012).  Similar findings of 
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activation of the ipsilateral inferior posterior hypothalamic region was also observed during 
SUNCT attacks and therefore the same DBS target was proposed to be potentially beneficial 
in the treatment of short lasting unilateral neuralgiform headache attacks (May et al., 1999).  
Only three case reports have been published, all showing substantial and sustained reductions 
in attack frequency without any serious adverse events (Leone et al., 2005, Lyons et al., 2009, 
Bartsch et al., 2011).  Since the initial work of May and Leone, further anatomical clarification 
of the surgical target has been undertaken and the target has been shown to be in the ventral 
tegmental area of the midbrain rather than the posterior hypothalamic region (Fontaine et al., 
2010, Matharu and Zrinzo, 2010). 
Our series shows improvements in both attack frequency (78%) and severity (50%) with VTA-
DBS.  This finding has been described in CCH cases treated with VTA-DBS but not short 
lasting unilateral neuralgiform headache attack cases (Magis and Schoenen, 2012).  This series 
also reports the headache load (HAL) as an outcome measure for the group.  This composite 
score reflects all three domains of headache burden (frequency, severity and duration).  Attack 
frequency has always been the focus of previous outcome reports for VTA-DBS for headache.  
However, the use of a single outcome may not represent the actual benefit perceived by the 
patient.  Headache load showed a significant improvement (99%) at final follow-up.  In our 
group, only one patient showed a discrepancy between attack frequency and HAL response 
(P9).  This patient exhibited a 66% reduction in attack frequency (and so a positive response 
to VTA-DBS) but a 48% reduction in HAL.  It is interesting to note that this patient stated they 
had not perceived any benefit from the treatment.  The clinical usefulness of HAL as a primary 
outcome measure needs validation in larger cohorts in the future. 
As in previous VTA-DBS for primary headache series our subjects reported a delay in clinical 
response.  In CCH this delay is several months long but in the short lasting unilateral 
neuralgiform headache cases ranged from days to a maximum of three months (Leone et al., 
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2005, Burns et al., 2009, Lyons et al., 2009, Bartsch et al., 2011, Magis et al., 2011, Magis and 
Schoenen, 2012).  In our series, the time taken to see positive clinical response was 1 month 
(range 1-2 months).  This delay likely reflects the neuroplastic response underlying successful 
VTA-DBS treatment. 
Clinically and statistically important differences were seen in HIT-6 scores following VTA-
DBS but no significant improvement was seen in quality of life measures.  Factors to consider 
in this observation include the small sample size, the long duration of chronic pain (9 years) 
and co-morbidities in these patients all of which may have resulted in psychosocial issues 
unlikely to improve with change in symptoms.  Similar observations have been made in VTA-
DBS for CCH (Bartsch et al., 2008).   Little has been published regarding quality of life data 
in the trigeminal autonomic cephalalgias including short lasting unilateral neuralgiform attack 
disorders and no specific headache disability or quality of life scales exist for these conditions.  
It has been suggested that in headache conditions, generic scales (such as SF36) may not be 
useful in measuring changes over time and that condition specific measures (such as HIT-6) 
may be more representative (Solomon, 1997).  Until such scales have been developed the 
quality of life tools available may not accurately reflect the headache groups they are applied 
to. 
Only one serious adverse event of subcutaneous infection leading to system removal was seen 
in our series.  Infection of the DBS system has been reported by two other CCH series (4/19 
and 1/11 patients) (Fontaine et al., 2010, Leone et al., 2013), although their operative technique 
differed from our unit. The death of a patient from an intracerebral haemorrhage following 
microelectrode (MER) guided DBS for CCH has raised serious safety concerns regards this 
procedure. However, there is no recognised neuronal firing pattern or “signature” for the VTA, 
casting doubt on the clinical utility of MER for this anatomical target. Moreover, the use of an 
MRI-verified surgical technique without the use of MER is associated with a significantly 
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lower risk of haemorrhage during DBS procedures (Zrinzo et al., 2012).  The stimulation 
induced ophthalmic side effects reported by our patients have all been documented in CCH 
series and, much like our series, have all been transient.  It is likely that this transient vertical 
diplopia is due to stimulation of the nearby rostral interstitial nucleus of the medial longitudinal 
fasciculus that forms part of the vertical gaze center (Buttner-Ennever et al., 1982).  
The main limitation of this study is the lack of placebo control.  Although there is undoubtedly 
a placebo effect for headache treatments it is unlikely our findings can be explained by this 
alone.  Placebo response rates for ONS in migraine are low (below 20%) and there is no reason 
to expect this not to be true in this condition or procedure (Lipton et al., 2009, Saper et al., 
2011, Silberstein et al., 2012).  Likewise, the intractable nature of the group, the sustained 
response and the re-emergence of attacks when stimulation was stopped all argue against a 
placebo response.  Although a previous randomized controlled trial of DBS in CCH failed to 
show a difference between sham and active stimulation this was likely due to methodological 
issues with a too short 1-month crossover periods.  Unfortunately, given the rarity of short 
lasting unilateral neuralgiform headache attacks it seems unlikely that high quality, properly 
powered randomised control trials of VTA-DBS will ever be performed.   
Microvascular decompression, occipital nerve stimulation and deep brain stimulation have all 
been found to be effective in open-label series with response rates of over 75% (Leone et al., 
2005, Bartsch et al., 2011, Sebastian et al., 2013, Lambru et al., 2014).  The invasiveness of 
surgery, associated risks, the need for implanted hardware and the cost of treatment will all 
influence individual patient options.  With these in mind, we may in the future recommend that 
patients with intractable short lasting unilateral neuralgiform headache attacks first undergo 
microvascular decompression if they have ipsilateral neurovascular compression of the 
trigeminal nerve, that ONS be reserved for those without neurovascular compression or failing 
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microvascular decompression and DBS (as the most invasive neuromodulation option) be left 
as an option when patients have failed all other procedures. 
This study suggests that VTA-DBS may provide an effective and sustained benefit in 
intractable short lasting unilateral neuralgiform headache attacks. However, MRI-verified 
VTA-DBS should be reserved for those patients having failed all other medical and surgical 
options available to them. 
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Short lasting unilateral neuralgiform headache attacks 
 At least 20 attacks suffered 
 Moderate to severe unilateral head pain with trigeminal distribution, lasting 1-600 
seconds and occurring as single stabs, series of stabs or in a saw-tooth pattern 
 At least one cranial autonomic symptom or sign ipsilateral to the pain: 
 Conjunctival injection and/or lacrimation 
1. nasal congestion and/or lacrimation 
2. eyelid oedema 
3. facial sweating 
4. facial flushing 
5. fullness in the ear 
6. ptosis and/or miosis 
 Attacks occur at least once a day for more than half the time the disorder is active 
Short lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing 
 As short lasting unilateral neuralgiform headache attacks 
 Autonomic symptoms of both conjunctival injection and lacrimation 
Short lasting unilateral neuralgiform headache attacks with autonomic features 
 As short lasting unilateral neuralgiform headache attacks 
 Autonomic symptoms include only one of or neither of conjunctival injection and 
lacrimation 
 
Table 1: International Classification of Headache Disorders diagnostic criteria for short lasting 
unilateral neuralgiform headache attacks. 
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 Age/ 
years 
Sex SUNCT/SUNA Chronic 
duration 
Side Other  
Headaches 
Attack 
Frequency/ 
Day 
Average 
Attack 
duration 
Triggered attacks/ 
Spontaneous 
attacks/Both* 
MRI for 
neurovascular 
conflict** 
1 56 M SUNCT 14 R NIL 20 5min Spontaneous NIL 
2 63 M SUNCT 16 R NIL 360 10 sec Both-touch/wind Right 
3 39 M SUNCT 9 R CCH (R) 
CM 
20 15 sec Spontaneous NIL 
4 67 M SUNCT 13 L CCH (L) 40 10min Spontaneous NIL 
5 64 F SUNCT 9 R NIL 6 3min Spontaneous NIL 
6 55 F SUNCT 20 L CM 120 2 min BOTH – 
touch/chewing/ 
wind 
NIL 
7 41 F SUNCT 4 L 
90% 
R 
10% 
NIL 200 3 min Spontaneous NIL 
8 26 F SUNA 8 R NIL 800 2 sec BOTH – 
talking/touch/ 
eating/wind 
NIL 
9 50 M SUNCT 6 L 
70% 
R 
30% 
CCH (L) 3 5min Spontaneous NIL 
10 42 M SUNA 
 
19 L 
40% 
R 
60% 
CM 95 2min Spontaneous NIL 
11 46 M SUNA 9 R NIL 45 30 sec  Spontaneous Right 
Median 
(IQR) 
50 
(22) 
7M 
3F 
8 SUNCT 
3 SUNA 
9 
(7) 
6 R 
2 L 
3L/R 
3 CCH 
3 CM 
45 
(20) 
2 min 
(5) 
8 Spontaneous 
3 Both 
2 Ipsilateral  
neurovascular 
conflict 
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*In case of triggered attacks, typical triggers are listed 
** Neurovascular conflict of trigeminal nerve at level of root entry zone seen on MRI 
M, male; F, female; SUNCT, short lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing; SUNA, short lasting unilateral 
neuralgiform headache attacks with autonomic features; R, right; L, left; L/R, left or right; CCH, chronic cluster headache; CM, chronic migraine; MO, 
medication overuse 
 
Table 2: Patient demographics 
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 Follow 
Up/ 
months 
DAILY ATTACK 
FREQUENCY 
ATTACK SEVERITY HEADACHE LOAD ATTACK DURATION  
(seconds) 
Estimated 
ImprovementŦ 
Patient 
recommendŦŦ 
  Pre 
DBS 
Post 
DBS 
% 
Change 
Pre 
DBS 
Post 
DBS 
% 
Change 
Pre 
DBS 
Post 
DBS 
% 
Change 
Pre 
DBS 
Post 
DBS 
% 
Change 
  
1 63 20 6 70 8 2 75 69 3 96 18000 30 99 95 Yes 
2 40 360 0 100 7 0 100 14 0 100 10 0 100 100 Yes 
3 33 10 0 100 10 0 100 7 0 100 15 0 100 100 Yes 
4 41 40 2 95 7 7 0 94 1 99 36000 1 100 70 Yes 
5 32 6 4 33 10 10 0 42 35 17 10800 7200 33 5 Yes 
6 ≠ 29 120 90 25 9 10 0 225 304 0 7200 7200 0 0 Yes 
7 23 200 58 71 10 5 50 1400 304 78 10800 60 99 70 Yes 
8 14 800 0 100 10 0 100 62 0 100 2 0 100 100 Yes 
9 7 3 1 66 10 10 0 23 12 48 18000 18000 0 0 Yes 
10 29 95 0 100 10 0 100 44 0 100 7200 0 100 100 Yes 
11 28 45 5 89 8 8 0 56 12 79 2160 18000 -7 58 Yes 
MEDIAN 
(IQR) 
29 
(20) 
45 
(20) 
2 
(10) 
78* 
(33) 
10 
(2) 
5 
(10) 
50* 
(100) 
62 
(202) 
3 
(35) 
99* 
(52) 
7200 
(17985) 
30 
(7200) 
99 
(100) 
70 
(95) 
 
*p<0.05 
Ŧ Patient estimate of improvement at final follow-up 
ŦŦ Patient asked if they would recommend the procedure to another person with short lasting unilateral neuralgiform headache attacks 
≠ Deep brain stimulation system removed at time of follow-up 
DBS, Deep brain stimulation 
Table 3: Headache characteristics before and after treatment 
The average daily attack frequency and severity is listed before and after treatment.  Headache load, a composite score reflecting attack frequency, severity 
and duration is also shown.  Patient satisfaction is shown using their estimated level of improvement and their recommendation of treatment to other 
patients. 
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 Pre-DBS 
Median (IQR) 
Post-DBS 
Median (IQR) 
Median % Change 
% (IQR) 
P-value 
MIDAS 81 (254) 65 (12) 0 (63) 0.678 
HIT-6 70 (12) 65 (14) 8 (19) 0.015* 
HAD-A 12 (11) 8 (13) 17 (28) 0.035* 
HAD-D 12 (8) 11 (10) 0 (42) 0.721 
BDI-II 23 (23) 16 (29) 0 (24) 0.929 
SF-36 Physical 23 (26) 29 (18) 0 (24) 0.594 
SF-36 Mental 30 (27) 46 (27) 23 (39) 0.208 
Euro-QoL 0.63 (0.18) 0.64 (0.18) 0 (1.0) 0.208 
Euro-Scale 30 (50) 32 (50) 0 (45) 0.483 
 
Table 4: Headache specific disability, affect and quality of life score changes with deep brain stimulation 
IQR, Interquartile range; MIDAS, Migraine Disability Assessment Scale; HIT-6, Headache Impact Test; HAD-A, Hospital Anxiety and Depression scores-anxiety 
specific; HAD-D, Hospital Anxiety and Depression scores – depression specific; BDI-II, Becks Depression Inventory; SF-36, Short Form 36. 
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Adverse Event (n) Resolution (surgical/medical/spontaneous/no intervention) 
Hardware Related  
IPG “flips” or moves in chest skin pocket (1) Surgical intervention – repositioning of IPG 
Biological 
Neck stiffness (3) No intervention 
Pain over wound site (2) No intervention 
Keloid scar over IPG site (1) No intervention 
Wound infection (1) Surgical intervention – removal of system 
Wound dehiscence, no infection (1) Medical  
Stimulation Related 
Diplopia, nausea, vertigo, ophthalmoplegia with changes of programming (11) Spontaneous 
Possible worsening of nausea (1) Medical – DBS switched off with no change in symptoms.  
Decision made symptoms not related to DBS 
Oscillopsia when reading (1) Spontaneous resolution after 6 weeks 
 TOTAL SURGICAL INTERVENTIONS = 2 
IPG, implantable pulse generator; DBS, deep brain stimulation 
Table 5: Adverse events related to deep brain stimulation  
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Figure 1: 1.5T MRI scan showing DBS lead placement 
Post-operative 1.5T T2-weighted, 2mm-thick, axial stereotactic MRI immediately after 
implant shows the DBS lead positioned in the right ventral tegmental area of the midbrain 
(white arrow)
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DBS, deep brain stimulation 
 
Figure 2: Reduction in daily attack frequency following deep brain stimulation 
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Figure 3: SF36 domain scores pre and post-DBS PF, physical functioning; RP, role-physcial; BP, bodily pain; GH, general health; VT, 
vitality; SF, social functioning; RE, role-emotional; MH, mental health; PCS, physical composite score; MCS,mental health composite score 
 
Running Title: DBS SUNCT/SUNA 
Pg. 34 
 
 
 
 Lamotrigine Topiramate Gabapentin Pregabalin Carbamazepine Oxcarbazepine Other 
1 600mg 350mg 3600mg 600mg 1600mg NT Melatonin 
Indometacin 
2 400mg 400mg DUK DUK 800 300 Melatonin, Baclofen, Phenytoin 
3 600mg 1000mg 3600mg 600mg DUK NT Duloxetine, Melatonin, Venlafaxine 
4 200mg 200mg 3600mg 300mg NT 1500mg Duloxetine, Melatonin 
5 600mg 400mg DUK DUK 900mg 300mg Duloxetine, Mexiletine, Melatonin, ONS 
6 200mg 450mg 2400mg 50mg 1200mg 1200mg Duloxetine, Lacosamide, Phenytoin, Baclofen, 
Zonisamide 
7 400mg 300mg 2700mg 300mg DUK 2400mg Duloxetine, Indometacin 
8 1200mg 400mg 1800mg 300mg 1200mg 1200mg Duloxetine, Baclofen, Lacosamide, VNS 
9 400mg 200mg 600mg 600mg NT NT  
10 400mg 200mg 900mg 600mg DUK 2100mg Duloxetine, Mexiletine, Lacosamide, Ketamine 
11 200mg 25mg 300mg 1200mg NT 1500mg Duloxetine, Indometacin 
NT, drug not tried; DUK, dose unknown; ONS, occipital nerve stimulation; VNS, non-invasive vagal nerve stimulation (GammaCore) 
Supplementary Table 1: Preventative medications previously tried by patients undergoing deep brain stimulation 
Table Legend: The daily dose of the preventative medications with stated efficacy in short lasting unilateral neuralgiform headache attacks taken by each 
patient prior to undergoing deep brain stimulation.  A list of additional medications trialled for the condition is also shown. 
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 Lidocaine Infusion (7-10 days) Greater Occipital Nerve Injection (lidocaine and steroid) 
 Response* Number of treatments Duration of response (days) Response** Side of injection Duration of response (days) 
1 Yes  1 10 days No Right 3 days 
2 Yes 1 On infusion only++ No Right 0 days 
3 Yes 1 On infusion only++ No Right 0 days 
4 Yes 1 On infusion only++ No  Left 0 days 
5 Yes 2 On infusion only++ No Right 0 days 
6 No 1 Nil No Left 0 days 
7 Yes 7 1 month  No Left 0 days 
8 Yes 1 On infusion only++ No Right 0 days 
9 N/A - - No Bilateral 0 days 
10 Yes 4 10 days Yes Bilateral 2 weeks 
11 Yes 2 Infusion only++ No Bilateral  5 days 
 
*Response defined by at least 50% reduction in daily attack frequency  
** Response defined by at least a 50% reduction in attack frequency for at least one week post procedure 
++ Patient reported response only during time on treatment and which stopped as soon as infusion ended 
N/A, patient not tried treatment 
Supplementary table 2: Injectable transitional treatments given for short lasting unilateral neuralgiform headache attacks prior to deep brain 
stimulation. 
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 Medication Prior to DBS Medication Post DBS Reduction in Dose 
1 Pregabalin 600mg 
Lamotrigine 600mg 
Pregabalin 600mg 
Lamotrigine 600mg 
No 
No 
2 Lamotrigine 700mg 
Carbamazepine 800mg 
Lamotrigine 400mg 
Oxcarbazepine 300mg 
Yes 
Yes (relative doses) 
3 Lamotrigine 600mg Nil Yes 
4 Nil Nil N/A 
5 Lamotrigine 600mg 
Topiramate 400mg 
Lamotrigine 600mg 
Lacosamide 50mg 
No 
No 
6 Zonisamide 100mg 
Lamotrigine 200mg 
Zonisamide 100mg 
Lamotrigine 200mg 
No 
No 
7 Oxcarbazepine 1800mg 
Topiramate 300mg 
Nil Yes 
Yes 
8 Lamotrigine 600mg 
Lacosamide 300mg 
Lamotrigine 600mg 
Lacosamide 300mg 
No 
No 
9 Lamotrigine 400mg Nil Yes 
10 Topiramate 200mg Nil Yes 
11 Nil Nil N/A 
 
DBS, deep brain stimulation; N/A, not applicable as patient not on medication 
Supplementary table 3: Summary of changes in preventative medications following deep brain stimulation 
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 Implant Location Amplitude Range 
(V) 
Frequency (Hertz) Pulse width (s) Contact points settings* 
1 Right 1.3-3.0 185 60 C+/1- 
2 Right 1.5-3.0 185 60 C+/1- 
3 Right 2.4-3.0 185 60 C+/0-, C+/0-1- 
4 Left 1.3-3.5 185 60 C+/1-, C+/1-2- 
5 Right 0-2.6 185 60 C+/0-, C+/1- 
6 Left 0.0-3.0 185 60 C+/0-, C+/0-1- 
7 Bilateral 2.2-3.0 185 60 C+/1-, C+/0-1- 
8 Right 3.0-3.5 185 60 C+1-, C+/0-1- 
9 Bilateral 3.0 185 60 Left: C+/0-, C+/1-, C+/0-1- 
10 Bilateral 3.0-3.5 185 60 Left: C+/0-, C+/0-1- 
Right: C+/9-, C+/8-9- 
11 Right 1.5-2.8 185 60 C+/1-, C+/0- 
Median 
(IQR) 
6 Right 
2 Left 
3 Bilateral 
 
1.5 (2.7)-3 (0.5) 
185 60  
 
*Lead set as cathode and contact point as anode 
Supplementary Table 4: Summary of deep brain stimulator settings for each patient  
 
